Related Experiment Video
Updated: Dec 16, 2025
07:00
Failure of Cleaning Verification in Pharmaceutical Industry Due to Uncleanliness of Stainless Steel Surface
Published on: August 11, 2017
8.6K
Seeking value in pharmaceutical care: balancing quality, access and efficiency
Terrence Montague1, Siobhan Cavanaugh
1Department of Patient Health, Merck Frosst Canada Ltd., Toronto, Ontario, Canada.
Healthcarepapers
|April 29, 2004
Summary
Balancing drug value, accessibility, and affordability is key for Canadian healthcare. Demand-side strategies and partnerships improve health outcomes and resource use, benefiting patients and providers.
Area of Science:
- Health Economics
- Pharmaceutical Policy
- Population Health Management
Background:
- Healthcare systems face challenges balancing drug value, accessibility, and affordability.
- Innovative drugs offer significant health and economic benefits, leading to increased demand and expenditure.
- Current supply-side cost-control strategies can limit population health benefits.
Discussion:
- Demand-side management strategies empower providers and patients, aligning with increasing stakeholder knowledge and accountability.
- A combination of strategies is likely optimal for managing innovative drug therapy.
- The partnership-measurement model in disease management demonstrates a practical, community-level approach.
Key Insights:
- Restricting drug access to control costs is suboptimal for overall population health.
- Empowering patients and providers through demand-side strategies is more effective.
- Community-level disease management models foster accountable and cost-efficient outcomes.
Outlook:
- Future strategies should focus on informed resource allocation for innovative drug therapies.
- Widening the debate on drug policy will lead to better health outcomes at optimal costs.
- Continuous improvement in outcomes is driven by real-world feedback and education.
Related Concept Videos
01:22Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
100
Body:Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug...
100
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
134
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
134
01:26Pharmaceutical Equivalents
128
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
128
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
99
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
99
01:19Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
93
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
93
01:16Bioequivalence: Overview
1.6K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.6K